Matching-Adjusted Indirect Comparisons of Diroximel Fumarate, Ocrelizumab, and Interferon beta-1a

被引：0
|
作者：
Hersh, Carrie [1 ]
Aladro-Benito, Yolanda [2 ]
Lewin, James B. [3 ]
Shen, Changyu [3 ]
Bozin, Ivan [4 ]
Sun, Zhaonan [3 ]
机构：
[1] Cleveland Clin, Clin Lou Ruvo Ctr Brain Hlth Las Vegas, Las Vegas, NV USA
[2] Hosp Univ Getafe, Madrid, Spain
[3] Biogen, Cambridge, MA USA
[4] Biogen, Baar, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P831/1806
引用
收藏
页码：641 / 641
页数：1
相关论文
共 50 条
  • [31] Alternative Weighting Approaches for Anchored Matching-Adjusted Indirect Comparisons via a Common Comparator
    Petto, Helmut
    Kadziola, Zbigniew
    Brnabic, Alan
    Saure, Daniel
    Belger, Mark
    VALUE IN HEALTH, 2019, 22 (01) : 85 - 91
  • [32] COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
    Aliya Jaber
    Meera Patel
    Andrew Sylvester
    Mary Yarussi
    J. Tamar Kalina
    Jason P. Mendoza
    Robin L. Avila
    Matthew A. Tremblay
    Neurology and Therapy, 2023, 12 : 687 - 700
  • [33] METHODOLOGICAL APPROACHES FOR CONDUCTING MATCHING-ADJUSTED INDIRECT COMPARISONS INVOLVING MULTIPLE RANDOMIZED CONTROLLED TRIALS
    Cameron, C.
    Varu, A.
    Disher, T.
    Hutton, B.
    VALUE IN HEALTH, 2018, 21 : S400 - S400
  • [34] COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
    Jaber, Aliya
    Patel, Meera
    Sylvester, Andrew
    Yarussi, Mary
    Kalina, J. Tamar
    Mendoza, Jason P.
    Avila, Robin L.
    Tremblay, Matthew A.
    NEUROLOGY AND THERAPY, 2023, 12 (02) : 687 - 700
  • [35] Matching-Adjusted Indirect Comparisons of Axicabtagene Ciloleucel to Mosunetuzumab for the Treatment of Relapsed/ Refractory Follicular Lymphoma
    Ray, Markqayne D.
    Kanters, Steve
    Beygi, Sara
    Best, Timothy
    Wulff, Jacob
    Limbrick-Oldfield, Eve
    Patel, Anik R.
    Oluwole, Olalekan O.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (09): : 885e1 - 885e11
  • [36] MATCHING-ADJUSTED INDIRECT COMPARISONS OF AVAPRITINIB VERSUS MIDOSTAURIN AMONG PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
    Pilkington, H.
    Smith, S.
    Roskell, N.
    Iannazzo, S.
    VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
  • [37] SC peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 5 Phase 3 trials
    Coyle, Patricia
    Shang, Shulian
    Castrillo-Viguera, Carmen
    NEUROLOGY, 2017, 88
  • [38] Two-stage matching-adjusted indirect comparison
    Remiro-Azocar, Antonio
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [39] SC peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 7 Phase 3 trials
    Coyle, P.
    Shang, S.
    You, X.
    Castrillo-Viguera, C.
    Fiore, D.
    Werneburg, B.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 776 - 776
  • [40] ECONOMIC IMPLICATIONS OF REPLACING INTERFERON BETA-1A WITH OCRELIZUMAB IN RELAPSING MULTIPLE SCLEROSIS
    Thomas, N.
    Ma, E.
    Yu, E. B.
    VALUE IN HEALTH, 2017, 20 (05) : A191 - A191
12345